Your AI-Trained Oncology Knowledge Connection!
This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.
Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment with ruxolitinib has been initiated.
Expert panelists highlight the COMFORT I and COMFORT II studies.
Key findings from COMFORT I and COMFORT II studies are examined.
Medical experts discuss strategies to navigate a complex patient scenario pertaining to previous refusal of ASCT.
Prithviraj Bose, MD, introduces study designs for trials focusing on JAK inhibitor utilization in patients receiving treatment for myelofibrosis.
The panel of experts dissect findings around breaking JAK inhibitor data in myelofibrosis treatment.
Dr Bose drives a discussion surrounding the treatment of advanced polycythemia vera.
Downstream impacts of ruxolitinib in polycythemia vera treatment are illustrated by a panel of medical experts.
This segment discusses the key efficacy and safety considerations from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b as a treatment option for polycythemia vera.
With their final discussion the panel examines the survival outcomes and risk of thromboembolic/hemorrhagic events from the MAJIC-PV trial, which compared ruxolitinib to best available therapy in polycythemia vera patients resistant or intolerant to hydroxyurea.
